**Tauopathy**

**Tauopathy**

[15] Biessels GJ, Reijmer YD. Brain MRI in children with type 1 diabetes: Snapshot or road

[16] Trofimova AV, Gaikova ON, Anan'eva NI, et al. Perivascular spaces: Morphology, neuroimaging, atypical variants. Radiation Diagnostics and Therapy. 2011;**2**(2):37-44 [17] Ho MS, Weller NJ, Ives FJ, et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. The Journal of Pediatrics. 2008;**153**(3):385-390

[18] Hoogma RP, Moll AC, Snock FJ, Stain CJ, Diamant M. Functional brain connectivity and neurocognitive functioning in patients with longstanding type 1 diabetes with and

[19] Perantie DC, Koller JM, Weaver PM, Lugar HM, Black KJ, White NH, Hershey T.Prospectively determined impact of type 1 diabetes on brain volume during development. Diabetes.

[20] Rizzo MR, Marfella R, Barbieri M, et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care.

[21] Zhong Y, Zhang XY,Miao Y, Zhu JH, Yan H, Wang BY, Jin J, Hu TJ, Jia WP. The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients. Biomedical and Environmental Sciences. 2012;**25**(1):1-7. DOI: 10.3967/0895-3988.2012.01.001

[22] Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006;**67**:235-240. DOI: 10.1212/

[23] Bogdan AA, Khomenko Yu G, Kataeva GV, et al. Principles of grouping data in the evaluation of the results of multivocaval spectroscopic examination of the brain. Radiation

[24] Castillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy.

[25] Maheshwari SR, Fatterpekar GM, Castillo M, et al. Proton MR spectroscopy of the brain.

[26] Hill NR, Nick SO, Choudhary P et al. Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups Diabetes. Technology & Therapeutics.

without microvascular complications. Diabetes. 2009;**58**:2335-2343

map of development changes? Diabetes. 2014;**63**:62-64

32 Cognitive Disorders

2011;**60**:3006-3014. DOI: 10.2337/db11-0589

2010;**33**:2169-2174. DOI: 10.2337/dc12-0199

Diagnostics and Therapy. 2016;**4**(7):15-19

American Journal of Neuroradiology. 1996;**17**:1-15

Seminars in Ultrasound, CT, and MR. 2000;**21**:434-451

2011;**13**(9):921-928. https://doi.org/10.1089/dia.2010.0247

01.wnl.0000224760.22802.e8

Hao Chi, Tzu-Kang Sang and Hui-Yun Chang Additional information is available at the end of the chapter

Hao Chi, Tzu-Kang Sang and Hui-Yun Chang

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/intechopen.73198

#### **Abstract**

Tauopathy is a category of neurodegenerative diseases that are caused or associated with pathological tau protein. Some of the diseases are relatively common, which include Alzheimer's disease (AD) and various Parkinsonism (PD). Tau protein is a type of microtubule-associated protein (MAP), encoded by the gene MAPT (microtubule-associated protein tau). Normally, tau binds to microtubule, supporting the assembling and structure of cytoskeletons. However, in tauopathy, normal tau protein undergoes abnormal posttranslational modifications and detaches from microtubule; furthermore, they may aggregate forming paired helical filaments (PHF) or straight filaments (SF). Abundant PHF could be observed under microscope as fibrillary tangles. In this chapter, we will introduce the pathogenesis process of tauopathy with regard to the posttranslational modifications of the protein, the animal models, and the developing treatments against tauopathy from a clinical prospective.

DOI: 10.5772/intechopen.73198

**Keywords:** tau, phosphorylation, truncation, kinases, Alzheimer's diseases, clinical trials
